The DIO-NASH mice treated with the vehicle were insulin-resistant, indicated by the higher fasting insulin levels, higher homeostatic model assessment of insulin resistance (HOMA-IR) and lower quantitative insulin sensitivity check index (QUICKI) score both at the treatment start (week 0) and the treatment completion (week 12) as well as by the lower calculated plasma glucose disappearance rate (KITT) in the ipITT at week 10 compared with the vehicle (Figure 3). The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.